狄诺塞麦多久打一次？

Giant cell tumor of bone is a histologically benign but often aggressive skeletal tumor that mostly occurs in young adults aged 20 to 40 years old. The incidence rate in women is slightly higher than that in men, accounting for about 56.4%. Globally, giant cell tumor of bone accounts for approximately 4%-5% of all primary bone tumors. Compared with European and American populations, it is more common in China, accounting for approximately 20% of all primary bone tumors. (denosumab) is an effective drug for the treatment of giant cell tumor of bone. So how often does it need to be administered?

According to the drug instructions, the recommended usage and dosage of denosumab (denosumab) is: (1) Denosumab (denosumab) can only be injected subcutaneously, not intravenously, intramuscularly, or intradermally. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 20 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Hypocalcemia must be corrected before initiating treatment with denosumab. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D. Patients who are concurrently taking immunosuppressants or have compromised immune systems may be at increased risk for serious infections, and physicians need to fully consider the benefit-risk ratio before prescribing denosumab to these patients.

Recommended related hot articles: /newsDetail/77873.html